An Insight into the Peculiarities of Signet-Ring Cell Carcinoma of The Colon – a Narrative Review

Author(s) :

Loredana Farcaș1, Diana Voskuil-Galoș2

1 University of Medicine and Pharmacy” Iuliu Hațieganu” Cluj-Napoca, Romania

2 Department of Oncology, Institute of Oncology “Prof. Dr. Ion Chiricuta” Cluj-Napoca, Romania

Corresponding author: Loredana Farcaș, Email:

Published: Volume IV, Issue 1, 1 May 2024, -



May 1, 2024 0 Comments



ntroduction: Signet-ring cell carcinoma of the colon (SRCC) is a rare, distinct entity of colon cancer, harboring a poor prognosis. Despite the quick development of a variety of personalized cancer treatments, no specific therapy is recommended for this histological subtype.

Material and method: We searched for articles published from 2010 to 2023 on PubMed-indexed journals using the following keywords: ”colon cancer”, ”signet-ring cell carcinoma”, ”epidemiology” “tumor marker”, ”microsatellite instability”, ”surgery”, ”neoadjuvant therapy”, “adjuvant therapy”.

Results: We selected29 studies that presented particularities of clinical presentation, preoperative work-up and treatment SRCC. Irrespective of age and gender, SRCC is located more frequently in the ascending colon, with patients having a more advanced stage at diagnosis. The ability of imaging techniques and tumor markers to indicate the full extent of the tumor is low. Consequently, a curative surgical approach is rarely possible, with many cases undergoing an incomplete resection. Although research regarding the role of neoadjuvant therapy in SRCC is limited, adjuvant chemotherapy seems to improve the outcomes for stage III SRCC. The incidence of BRCA1 and B-RAF gene mutations is higher compared to adenocarcinoma tumors, as well as the presence of microsatellite instability, which qualifies SRCC for a more targeted treatment.

Conclusion: Considering the aggressiveness of this histological subtype, the work-up of patients with SRCC requires further improvement. Additionally, more in depth research into specific biomarkers, including circulating tumor DNA is needed for a tailored therapeutic strategy.

Notify of
Inline Feedbacks
View all comments